Claims for Patent: 6,471,958

Summary for Patent: 6,471,958

Title:	Non-contracting tissue equivalent
Abstract:	The present invention provides a non-contracting tissue equivalent comprising at least one cellular component and at least one non-cellular component. The tissue equivalent closely resembles normal tissue in being substantially non-contracting. In addition, the non-contracting tissue equivalent is translucent, allowing direct visual observation of the different layers of cells in the tissue equivalent. The non-contracting tissue equivalent is useful for a variety of complete tissue replacements including skin and cornea. The non-contracting tissue equivalent is useful for in vitro testing, evaluation and screening of potential pharmaceuticals or consumer products, production of biocompatible clinical products for tissue replacement and augmentation, and research studies on fundamental aspects of tissue structure and function. The capability for direct visual observation of layers of cells permits manual or automated assessment of important biological parameters of the tissue, including cell viability, proliferation, motility, and differentiation.
Inventor(s):	Dimitrijevich; S. Dan (Bedford, TX), Gracy; Robert W. (Fort Worth, TX)
Assignee:	University of North Texas Health Science Center (Fort Worth, TX)
Application Number:	09/775,843
Patent Claims:	1. A method of making a tissue equivalent which comprises the steps of combining an aqueous suspension of initial mesenchymal cells in a substantially serum-free nutrient medium at a temperature below about ambient temperature with a solution of collagenous material to produce a gelable admixture; solidifying the admixture by gelation to a translucent collagenous matrix; thereafter combining said translucent collagenous matrix with an aqueous suspension of other mesenchymal cells; and incubating the resulting combination for a time period sufficient for said other mesenchymal cells to attach to said collagenous matrix, wherein the cell density of the tissue equivalent is in the range of about 1.0.times.10.sup.5 cells/ml and the collagen concentration of the tissue equivalent is in the range of about 3 to about 5 mg/ml. 2. The method of claim 1 wherein the collagenous material is a member of the group consisting of collagen I, collagen III, collagen IV, fibrin, fibronectin and mixtures thereof. 3. The method of claim 1 wherein an additional collagenous material is combined with said translucent collagenous matrix. 4. The method of claim 3 wherein the additional collagenous material is a member of the group consisting of collagen I, collagen III, collagen IV, fibrin, fibronectin and mixtures thereof. 5. The method of claim 1 wherein the additional collagenous material is collagen IV. 6. The method of claim 1 wherein the initial mesenchymal cells are members of the group consisting of fibroblasts, keratinocytes, keratocytes, melanocytes, corneal fibroblasts, corneal epithelial cells and corneal endothelial cells. 7. The method of claim 1 wherein the other mesenchymal cells are members of the group consisting of fibroblasts, keratinocytes, melanocytes, corneal fibroblasts, corneal epithelial cells and corneal endothelial cells. 8. The method of claim 1 wherein the other mesenchymal cells are keratinocytes. 9. The method of claim 1 comprising the additional step of contacting the produced tissue equivalent with further mesenchymal cells which are members of the group consisting of fibroblasts, keratinocytes, melanocytes, corneal fibroblasts, corneal epithelial cells and corneal endothelial cells. 10. The method of claim 9 wherein the initial mesenchymal cells are corneal fibroblasts. 11. The method of claim 9 wherein the other mesenchymal cells are corneal endothelial cells. 12. The method of claim 9 wherein the further mesenchymal cells are melanocytes. 13. The method of claim 10 wherein the other mesenchymal cells are corneal epithelial cells. 14. The method of claim 3 wherein the additional collagenous material is a mixture of fibronectin and laminin. 15. The method of claim 3 wherein the additional collagenous material is a mixture of fibronectin, collagen and laminin. 16. A substantially non-contracting tissue equivalent which comprises an uncontracted collagenous matrix and a plurality of mesenchymal cells retrained within said matrix; said collagenous matrix being substantially free from covalent crosslinks and dissociated by mild treatment with collagenase, wherein the substantially non-contractile characteristic of said tissue equivalent is independent of cell density in the range of about 1.0.times.10.sup.5 to about 5.0.times.10.sup.5 cells/ml, and is independent of collagen concentration in the range of about 3 to about 5 mg/ml. 17. The tissue equivalent of claim 16, wherein the mesenchymal cells are members of the group consisting of fibroblasts, keratinocytes, melanocytes and mixtures thereof. 18. The tissue equivalent of claim 16, wherein the matrix is a member of the group consisting of collagen I, collagen III, collagen IV, fibrin, fibronectin and mixtures thereof. 19. The tissue equivalent of claim 16, wherein the mesenchymal cells are fibroblasts and the matrix is collagen I. 20. The tissue equivalent of claim 16, wherein a second cellular component comprising keratinocytes is present. 21. The tissue equivalent of claim 16, wherein the collagenous matrix is constitute by collagen I and collagen IV. 22. The tissue equivalent of claim 21, wherein the mesenchymal cells are members of the group consisting of fibroblasts, keratinocytes, melanocytes, corneal fibroblasts, corneal epithelial cells, corneal endothelial cells, and mixtures thereof. 23. The substantially non-contracting tissue equivalent of claim 21 wherein the mesenchymal cells are corneal fibroblasts and corneal endothelial cells. 24. The tissue equivalent of claim 21, which has been formed serum-free media and viably maintained in media comprising Ham's F-12 media supplemented with about 6.0 g/L glucose, no more than 2 mM calcium, about 50 .mu.gml .alpha.-ketoglutarate, about 27 mg/ml glycine, 50 .mu.g/ml ascorbate and no more than about 5% serum. 25. The tissue equivalent of claim 21, wherein said collagenous matrix is a three-dimensional collagenous matrix. 26. A method of making a tissue equivalent which comprises the steps of combining an aqueous suspension of mesenchymal cells in a substantially serum-free nutrient medium at a temperature below about ambient temperature with a solution of collagenous material to produce a gelable admixture; and solidifying the admixture by gelation at a pH of about 7 and a temperature of about 37.degree. C. to a translucent matrix; wherein the cell density of the tissue equivalent is in the range of about 1.0.times.10.sup.5 cells/ml and the collagen concentration of the tissue equivalent is in the range of about 3 to about 5 mg/ml. 27. The method in accordance with claim 26 wherein the nutrient medium contains no more than about 2 mM of calcium. 28. The method of claim 26 wherein the mesenchymal cells are members of the group consisting of fibroblasts, keratinocytes, melanocytes and mixtures thereof. 29. The method of claim 26, wherein the collagenous material is a member of the group consisting of collagen I, collagen III, collagen IV, fibrin, fibronectin and mixtures thereof. 30. The method of claim 26, wherein the mesenchymal cells are fibroblasts and the collagenous material is collagen I. 31. The method of claim 26 wherein the solidification is effected in an incubator at about 37.degree. C. 32. The method in accordance with claim 26 wherein the culture medium exhibits an oxygen partial pressure of at least about 300 millimeters of mercury but no more than about 1250 millimeters of mercury. 33. The tissue equivalent of claim 16 wherein a second cellular component comprising keratinocytes is present. 34. The substantially non-contracting tissue equivalent of claim 16 wherein the collagenous matrix is constituted by collagen I and collagen IV. 35. The substantially non-contracting tissue equivalent of claim 34 wherein the mesenchymal cells are members of the group consisting of fibroblasts, keratinocytes, melanocytes, corneal fibroblasts, corneal epithelial cells, corneal endothelial cells, and mixtures thereof. 36. The substantially non-contracting tissue equivalent of claim 34 wherein the mesenchymal cells are corneal fibroblasts and corneal endothelial cells.

Details for Patent 6,471,958

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2018-03-24